Journal Club: Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

Listen to a new Journal Club with PI Dr. Brian Slomovitz and moderator Dr. Leslie Randall as they discuss details on the New England Journal of Medicine published article Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.

Click here to read the article

Presented by
Brian Slomovitz
Director of Gynecologic Oncology 
Co-Chair, Cancer Research Committee
Mount Sinani Medical Center
USA

Moderated by
Leslie Randall
Director of Gynecologic Oncology Clinical Research and Gynecologic Cancer Service Line
Inova Schar Cancer Institute
Inova Health System 
USA

Supported in part by Pfizer | Genmab